ENCell Co., Ltd. (KOSDAQ:456070)
South Korea · Delayed Price · Currency is KRW 11,060
-400 (-3.49%)
May 20, 2026, 3:30 PM KST
ENCell Revenue
In the year 2025, ENCell had annual revenue of 5.26B KRW, down -27.06%. ENCell had revenue of 1.44B in the quarter ending December 31, 2025, a decrease of -31.07%.
Revenue
5.26B
Revenue Growth
-27.06%
P/S Ratio
23.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
126.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.26B | -1.95B | -27.06% |
| Dec 31, 2024 | 7.21B | -3.32B | -31.51% |
| Dec 31, 2023 | 10.53B | 3.16B | 42.87% |
| Dec 31, 2022 | 7.37B | 3.46B | 88.49% |
| Dec 31, 2021 | 3.91B | 2.50B | 178.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 195.27B |
| JETEMA, | 76.90B |
| Amicogen | 41.98B |
| CG Invites | 27.39B |
| GeneOne Life Science | 23.04B |
| Prestige BioPharma | 19.02B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |